Drug Trial Radar · NCT07707674
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Evopoint Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer
Conditions
- Metastatic Pancreatic Cancer
Interventions
XNW28012Drug
XNW28012 is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targeting Tissue Factor (TF) and a topoisomerase I inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.
- Incidence of Serious Adverse Events (SAEs)Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Karmanos Cancer Institute
Detroit, Michigan
START - Midwest
Grand Rapids, Michigan
START - New York Long Island
Lake Success, New York
Cleveland Clinic Foundation
Cleveland, Ohio
Oklahoma University Health Sciences Center
Oklahoma City, Oklahoma
SCRI Oncology Partners
Nashville, Tennessee
SCRI at Mary Crowley
Dallas, Texas
START - San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.